Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
174 hedge funds and large institutions have $1.52B invested in Acorda Therapeutics in 2014 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 63 increasing their positions, 58 reducing their positions, and 20 closing their positions.
60% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 20
60% more call options, than puts
Call options by funds: $13.3M | Put options by funds: $8.31M
7% more funds holding
Funds holding: 162 → 174 (+12)
9% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 58
3% more capital invested
Capital invested by funds: $1.47B → $1.52B (+$46.9M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.2M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$38.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$31.3M |
| 4 |
VAM
Visium Asset Management
New York
|
+$16.6M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$21M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.8M |
| 3 |
BM
Bridger Management
New York
|
-$14.5M |
| 4 |
Millennium Management
New York
|
-$13.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$11.8M |
ACOR Hedge Fund Activity: Q3 2014 in Review
174 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2014, worth a combined $1.52B — up 3.2% from $1.47B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ACOR positions and 20 closed out — a net gain of 12 holders — while 63 added to existing stakes and 58 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $42.2M. The largest seller was Citadel Advisors, cutting an estimated $21M.
- 174 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2014, up from 162 in Q2 2014.
- Funds reported $1.52B of Acorda Therapeutics stock for Q3 2014, up 3.2% quarter-over-quarter.
- 32 funds opened new Acorda Therapeutics positions in Q3 2014 and 20 closed out, a net change of +12 holders.
- The largest Acorda Therapeutics buyer in Q3 2014 was Fidelity Investments, an estimated $42.2M added.
- The largest Acorda Therapeutics seller in Q3 2014 was Citadel Advisors, an estimated $21M sold.
Based on aggregated 13F filings for Q3 2014.